Compare BKT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKT | AGEN |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.5M | 274.8M |
| IPO Year | 1994 | 1999 |
| Metric | BKT | AGEN |
|---|---|---|
| Price | $9.73 | $7.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 136.3K | ★ 873.0K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.96 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | N/A | $107.63 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.52 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $9.73 | $2.71 |
| 52 Week High | $11.49 | $8.85 |
| Indicator | BKT | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 28.03 | 54.50 |
| Support Level | N/A | $2.97 |
| Resistance Level | $10.65 | $8.64 |
| Average True Range (ATR) | 0.12 | 0.43 |
| MACD | -0.04 | -0.10 |
| Stochastic Oscillator | 17.84 | 54.07 |
Blackrock Income Trust Inc is a closed-end management investment company. Its investment objective is to manage a portfolio of high-quality securities to achieve both preservation of capital and high monthly income. The fund seeks to achieve its investment objective by investing at least 65% of its assets in mortgage-backed securities.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.